AbbVie Acquires Apogee Therapeutics for $10.9 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 47 minutes ago
0mins
Source: Fool
- Acquisition Overview: AbbVie is acquiring Apogee Therapeutics for $10.9 billion at $135.11 per share in cash, representing a 49% premium, aimed at enhancing its drug portfolio and expanding its market share in immunology.
- Pipeline Advantages: Apogee brings a promising pipeline of experimental drugs targeting dermatologic, respiratory, and other immunological diseases, particularly its lead candidate, zumilokibart, which could become a best-in-class treatment for atopic dermatitis with a more convenient dosing schedule.
- Strategic Significance: AbbVie's CEO highlighted that this acquisition will further enrich its immunology portfolio, addressing significant patient needs in areas like atopic dermatitis and asthma, thereby reinforcing the company's leadership in inflammatory disease treatment.
- Financial Outlook: Although the deal is expected to close in the third quarter, AbbVie does not anticipate any impact on adjusted earnings per share until 2032, indicating a long-term strategic approach to diversifying its revenue base.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 216.490
Low
223.00
Averages
252.00
High
289.00
Current: 216.490
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie Acquires Apogee Therapeutics for $10.9 Billion
- Acquisition Overview: AbbVie is acquiring Apogee Therapeutics for $10.9 billion at $135.11 per share in cash, representing a 49% premium, aimed at enhancing its drug portfolio and expanding its market share in immunology.
- Pipeline Advantages: Apogee brings a promising pipeline of experimental drugs targeting dermatologic, respiratory, and other immunological diseases, particularly its lead candidate, zumilokibart, which could become a best-in-class treatment for atopic dermatitis with a more convenient dosing schedule.
- Strategic Significance: AbbVie's CEO highlighted that this acquisition will further enrich its immunology portfolio, addressing significant patient needs in areas like atopic dermatitis and asthma, thereby reinforcing the company's leadership in inflammatory disease treatment.
- Financial Outlook: Although the deal is expected to close in the third quarter, AbbVie does not anticipate any impact on adjusted earnings per share until 2032, indicating a long-term strategic approach to diversifying its revenue base.
See More
AbbVie Acquires Apogee for $10.9 Billion to Strengthen Immunology Business
- Acquisition Overview: AbbVie is acquiring Apogee Therapeutics for $10.9 billion, paying $135.11 per share in cash, which represents a 49% premium over the stock's closing price prior to the announcement, aimed at diversifying its immunology business and enhancing profitability.
- Pipeline Potential: Apogee brings a promising pipeline of experimental drugs targeting dermatologic and respiratory diseases, with its lead candidate, zumilokibart, potentially being a best-in-class treatment for atopic dermatitis that offers a more convenient dosing schedule, addressing significant patient needs.
- Strategic Importance: AbbVie's CEO highlighted that this acquisition will expand its immunology portfolio in critical areas of patient need, helping to reduce reliance on blockbuster drugs Skyrizi and Rinvoq, which generated $6.6 billion in net revenue in the first quarter alone.
- Financial Outlook: While the acquisition is expected to close in the third quarter, AbbVie does not anticipate any contribution to its adjusted earnings per share until 2032, indicating a long-term strategic approach to enhancing its market position.
See More
Intel Shares Hit All-Time High as Market Confidence Grows
- Intel Stock Surge: Intel shares climbed to an all-time high of $141.45, driven by growing confidence in its chip manufacturing business and positive outlook on partnerships with major tech firms like Apple, which is expected to enhance future earnings.
- Keel Infrastructure Transformation: Keel Infrastructure reached a four-year high of $7.37 as investors welcomed its strategic shift from cryptocurrency mining to AI infrastructure, with the company raising $458 million to support its data center projects.
- Apogee Therapeutics Acquisition Boost: Apogee Therapeutics stock surged to $133 after AbbVie agreed to acquire the company for $135.11 per share in a $10.9 billion all-cash deal, indicating large pharmaceutical firms' ongoing interest in promising drug development.
- Strong Market Performance: Intel, Keel Infrastructure, and Apogee Therapeutics all achieved new 52-week highs, reflecting investor confidence in long-term growth in infrastructure, advanced computing, and healthcare sectors, with Intel and Keel both gaining over 5% and Apogee soaring 46%.
See More
Apogee Therapeutics Acquired by AbbVie at 49% Premium
- Merger Agreement: Apogee Therapeutics Inc. has officially signed a $10.9 billion acquisition agreement with pharmaceutical giant AbbVie Inc., with AbbVie set to acquire Apogee at $135.11 per share, representing a 49.5% premium over its closing price of $90.38 last Friday, indicating strong market confidence in the deal.
- Stock Surge: Following the acquisition announcement, Apogee's stock soared to a high of $133 before closing at $132.55, marking a 46.66% increase from the previous trading day, reflecting investor optimism about its future prospects.
- Strategic Importance: AbbVie's acquisition aims to strengthen its portfolio in immunology, as Apogee's diverse pipeline focuses on elevating care standards for patients with dermatologic, respiratory, and other related inflammatory and immunological diseases, further solidifying AbbVie's market position.
- Regulatory Approval Timeline: The transaction is subject to regulatory and shareholder approvals, with expectations for completion in the third quarter of this year, establishing a timeline for integration and future growth for both companies.
See More
AbbVie Acquires Apogee for Approximately $10.9 Billion
- Acquisition Overview: AbbVie has signed a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, totaling approximately $10.9 billion, which underscores AbbVie's robust presence and expansion strategy in the pharmaceutical market.
- Shareholder Value Enhancement: The agreed purchase price represents a nearly 47% premium over Apogee's previous closing price, which is expected to garner support from Apogee shareholders, further solidifying AbbVie's market position in the biopharmaceutical sector.
- Drug Development Potential: Apogee's leading drug, zumilokibart, has shown promising results in clinical trials for eczema and asthma, with its long-lasting effects providing a competitive edge in the market, likely contributing to significant future revenues for AbbVie.
- Financial Impact Analysis: Although the acquisition is projected to negatively impact AbbVie's non-GAAP EPS in the short term, analysts anticipate that the earnings per share will remain strong at $14.24 and $16.25 over the next two years, reflecting market confidence in AbbVie's stock.
See More
AbbVie Acquires Apogee for $10.9 Billion to Enhance Immunology Portfolio
- Acquisition Overview: AbbVie has signed a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion, paying $135.11 per share in cash, which represents a nearly 47% premium over Apogee's previous closing price, indicating strong market confidence in the deal.
- Drug Development Potential: Apogee's leading drug candidate, zumilokibart, is currently in Phase 2 trials for moderate-to-severe atopic dermatitis, with long-lasting effects that require administration only every three to six months, positioning it as a strong competitor against existing treatments if approved.
- Financial Impact Analysis: Although the acquisition is expected to reduce AbbVie's non-GAAP EPS by $0.14 in 2023 and $0.46 in 2027, analysts project EPS to reach $14.24 and $16.25 in the next two years, reflecting the long-term value of the acquisition.
- Strategic Growth Outlook: By acquiring Apogee, AbbVie further solidifies its position in the biopharmaceutical sector, with the transaction expected to close in Q3 2023, enhancing its competitiveness in the treatment of immune and inflammatory diseases and driving sustained growth for the company.
See More
AbbVie Acquires Apogee Therapeutics for $10.9 Billion
- Acquisition Overview: AbbVie is acquiring Apogee Therapeutics for $10.9 billion at $135.11 per share in cash, representing a 49% premium, aimed at enhancing its drug portfolio and expanding its market share in immunology.
- Pipeline Advantages: Apogee brings a promising pipeline of experimental drugs targeting dermatologic, respiratory, and other immunological diseases, particularly its lead candidate, zumilokibart, which could become a best-in-class treatment for atopic dermatitis with a more convenient dosing schedule.
- Strategic Significance: AbbVie's CEO highlighted that this acquisition will further enrich its immunology portfolio, addressing significant patient needs in areas like atopic dermatitis and asthma, thereby reinforcing the company's leadership in inflammatory disease treatment.
- Financial Outlook: Although the deal is expected to close in the third quarter, AbbVie does not anticipate any impact on adjusted earnings per share until 2032, indicating a long-term strategic approach to diversifying its revenue base.
See More
AbbVie Acquires Apogee for $10.9 Billion to Strengthen Immunology Business
- Acquisition Overview: AbbVie is acquiring Apogee Therapeutics for $10.9 billion, paying $135.11 per share in cash, which represents a 49% premium over the stock's closing price prior to the announcement, aimed at diversifying its immunology business and enhancing profitability.
- Pipeline Potential: Apogee brings a promising pipeline of experimental drugs targeting dermatologic and respiratory diseases, with its lead candidate, zumilokibart, potentially being a best-in-class treatment for atopic dermatitis that offers a more convenient dosing schedule, addressing significant patient needs.
- Strategic Importance: AbbVie's CEO highlighted that this acquisition will expand its immunology portfolio in critical areas of patient need, helping to reduce reliance on blockbuster drugs Skyrizi and Rinvoq, which generated $6.6 billion in net revenue in the first quarter alone.
- Financial Outlook: While the acquisition is expected to close in the third quarter, AbbVie does not anticipate any contribution to its adjusted earnings per share until 2032, indicating a long-term strategic approach to enhancing its market position.
See More
Intel Shares Hit All-Time High as Market Confidence Grows
- Intel Stock Surge: Intel shares climbed to an all-time high of $141.45, driven by growing confidence in its chip manufacturing business and positive outlook on partnerships with major tech firms like Apple, which is expected to enhance future earnings.
- Keel Infrastructure Transformation: Keel Infrastructure reached a four-year high of $7.37 as investors welcomed its strategic shift from cryptocurrency mining to AI infrastructure, with the company raising $458 million to support its data center projects.
- Apogee Therapeutics Acquisition Boost: Apogee Therapeutics stock surged to $133 after AbbVie agreed to acquire the company for $135.11 per share in a $10.9 billion all-cash deal, indicating large pharmaceutical firms' ongoing interest in promising drug development.
- Strong Market Performance: Intel, Keel Infrastructure, and Apogee Therapeutics all achieved new 52-week highs, reflecting investor confidence in long-term growth in infrastructure, advanced computing, and healthcare sectors, with Intel and Keel both gaining over 5% and Apogee soaring 46%.
See More
Apogee Therapeutics Acquired by AbbVie at 49% Premium
- Merger Agreement: Apogee Therapeutics Inc. has officially signed a $10.9 billion acquisition agreement with pharmaceutical giant AbbVie Inc., with AbbVie set to acquire Apogee at $135.11 per share, representing a 49.5% premium over its closing price of $90.38 last Friday, indicating strong market confidence in the deal.
- Stock Surge: Following the acquisition announcement, Apogee's stock soared to a high of $133 before closing at $132.55, marking a 46.66% increase from the previous trading day, reflecting investor optimism about its future prospects.
- Strategic Importance: AbbVie's acquisition aims to strengthen its portfolio in immunology, as Apogee's diverse pipeline focuses on elevating care standards for patients with dermatologic, respiratory, and other related inflammatory and immunological diseases, further solidifying AbbVie's market position.
- Regulatory Approval Timeline: The transaction is subject to regulatory and shareholder approvals, with expectations for completion in the third quarter of this year, establishing a timeline for integration and future growth for both companies.
See More
AbbVie Acquires Apogee for Approximately $10.9 Billion
- Acquisition Overview: AbbVie has signed a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, totaling approximately $10.9 billion, which underscores AbbVie's robust presence and expansion strategy in the pharmaceutical market.
- Shareholder Value Enhancement: The agreed purchase price represents a nearly 47% premium over Apogee's previous closing price, which is expected to garner support from Apogee shareholders, further solidifying AbbVie's market position in the biopharmaceutical sector.
- Drug Development Potential: Apogee's leading drug, zumilokibart, has shown promising results in clinical trials for eczema and asthma, with its long-lasting effects providing a competitive edge in the market, likely contributing to significant future revenues for AbbVie.
- Financial Impact Analysis: Although the acquisition is projected to negatively impact AbbVie's non-GAAP EPS in the short term, analysts anticipate that the earnings per share will remain strong at $14.24 and $16.25 over the next two years, reflecting market confidence in AbbVie's stock.
See More
AbbVie Acquires Apogee for $10.9 Billion to Enhance Immunology Portfolio
- Acquisition Overview: AbbVie has signed a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion, paying $135.11 per share in cash, which represents a nearly 47% premium over Apogee's previous closing price, indicating strong market confidence in the deal.
- Drug Development Potential: Apogee's leading drug candidate, zumilokibart, is currently in Phase 2 trials for moderate-to-severe atopic dermatitis, with long-lasting effects that require administration only every three to six months, positioning it as a strong competitor against existing treatments if approved.
- Financial Impact Analysis: Although the acquisition is expected to reduce AbbVie's non-GAAP EPS by $0.14 in 2023 and $0.46 in 2027, analysts project EPS to reach $14.24 and $16.25 in the next two years, reflecting the long-term value of the acquisition.
- Strategic Growth Outlook: By acquiring Apogee, AbbVie further solidifies its position in the biopharmaceutical sector, with the transaction expected to close in Q3 2023, enhancing its competitiveness in the treatment of immune and inflammatory diseases and driving sustained growth for the company.
See More
